NEW HIGHLIGHT
Pagenax

Pagenax

brolucizumab

Manufacturer:

Novartis

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Brolucizumab
Indications/Uses
Neovascular (wet) age-related macular degeneration (AMD) in adults.
Dosage/Direction for Use
Administer as intravitreal inj. Recommended dose: 6 mg (0.05 mL soln) every 4 wk (mthly) for the first 3 doses. May individualise treatment intervals based on disease activity as assessed by visual acuity &/or anatomical parameters usually 16 wk (4 mth) after start of treatment. Patient w/o disease activity Consider treatment every 12 wk (3 mth). Patient w/ disease activity Consider treatment every 8 wk (2 mth).
Contraindications
Hypersensitivity. Active or suspected ocular or periocular infections. Active intraocular inflammation.
Special Precautions
Monitor & manage for increased IOP & optic nerve head perfusion. Bilateral treatment. Retinal pigment epithelial tears. History of stroke, TIA or MI w/in last 3 mth. Endophthalmitis, intraocular inflammation, traumatic cataract, retinal detachment, retinal vasculitis, &/or retinal vascular occlusion. Discontinue in patients w/ rhegmatogenous retinal detachment or stage 3 or 4 macular holes. Not to be administered concurrently w/ other systemic or local anti-VEGF medicinal products. Minor influence on the ability to drive & use machines due to possible temporary visual disturbances. Women of childbearing potential should use effective contraception during treatment & for at least 1 mth after the last dose upon discontinuation of treatment. Not to be used during pregnancy. Not recommended during lactation.
Adverse Reactions
Hypersensitivity (eg, urticaria, rash, pruritus, erythema); reduced visual acuity, retinal & conjunctival haemorrhage, uveitis, iritis, vitreous detachment, retinal tear, retinal pigment epithelial tear, cataract, vitreous floaters, eye pain, increased IOP, conjunctivitis, blurred vision, corneal abrasion, punctate keratitis.
ATC Classification
S01LA06 - brolucizumab ; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.
Presentation/Packing
Form
Pagenax intraocular inj 120 mg/mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in